صورة الغلاف

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug-drug-gene interaction network

Abstract The antiarrhythmic agent quinidine is a potent inhibitor of cytochrome P450 (CYP) 2D6 and P‐glycoprotein (P‐gp) and is therefore recommended for use in clinical drug-drug interaction (DDI) studies. However, as quinidine is also a substrate of CYP3A4 and P‐gp, it is susceptible to DDIs invol...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Denise Feick (مؤلف), Simeon Rüdesheim (مؤلف), Fatima Zahra Marok (مؤلف), Dominik Selzer (مؤلف), Helena Leonie Hanae Loer (مؤلف), Donato Teutonico (مؤلف), Sebastian Frechen (مؤلف), Maaike van derLee (مؤلف), Dirk Jan A. R. Moes (مؤلف), Jesse J. Swen (مؤلف), Matthias Schwab (مؤلف), Thorsten Lehr (مؤلف)
التنسيق:	كتاب
منشور في:	Wiley, 2023-08-01T00:00:00Z.
الموضوعات:	article
الوصول للمادة أونلاين:	Connect to this object online.
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions
حسب: Helena Leonie Hanae Loer, وآخرون
منشور في: (2023)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
حسب: Helena Leonie Hanae Loer, وآخرون
منشور في: (2022)

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug-drug interaction predictions
حسب: Helena Leonie Hanae Loer, وآخرون
منشور في: (2024)

A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions
حسب: Christina Kovar, وآخرون
منشور في: (2024)

Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
حسب: Simeon Rüdesheim, وآخرون
منشور في: (2022)

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
حسب: Simeon Rüdesheim, وآخرون
منشور في: (2020)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
حسب: Laura Maria Fuhr, وآخرون
منشور في: (2021)

Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone
حسب: Simeon Rüdesheim, وآخرون
منشور في: (2022)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
حسب: Fatima Zahra Marok, وآخرون
منشور في: (2021)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling
حسب: Laura Maria Fuhr, وآخرون
منشور في: (2022)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
حسب: Hannah Britz, وآخرون
منشور في: (2019)

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
حسب: Jim J. Xiao, وآخرون
منشور في: (2019)

The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients
حسب: Qinglian Zhai, وآخرون
منشور في: (2024)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
حسب: Thomas Wendl, وآخرون
منشور في: (2022)

A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions
حسب: Denise Türk, وآخرون
منشور في: (2020)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators
حسب: Fatima Zahra Marok, وآخرون
منشور في: (2023)

FROG INTESTINAL PERFUSION TO EVALUATE DRUG PERMEABILITY: APPLICATION TO P-gp AND CYP3A4 SUBSTRATES
حسب: Neelima eYerasi, وآخرون
منشور في: (2015)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
حسب: Wang Q, وآخرون
منشور في: (2019)

Understanding CYP3A4 and P‐gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib
حسب: Christine Bowman, وآخرون
منشور في: (2024)

Prediction of Drug-Drug-Gene Interaction Scenarios of (<i>E</i>)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
حسب: Christina Kovar, وآخرون
منشور في: (2022)

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents
حسب: Matthias Hoch, وآخرون
منشور في: (2022)

Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement
حسب: Shashank Chaturvedi, وآخرون
منشور في: (2020)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
حسب: David Damoiseaux, وآخرون
منشور في: (2022)

Pharmacokinetic interaction between rhynchopylline and pellodendrine via CYP450 enzymes and P-gp
حسب: Qingzhen Meng, وآخرون
منشور في: (2021)

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
حسب: Margarida L. F. Martins, وآخرون
منشور في: (2022)

Insights into CYP2B6-mediated drug-drug interactions
حسب: William D. Hedrich, وآخرون
منشور في: (2016)

Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
حسب: Nicola Ferri, وآخرون
منشور في: (2023)

Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity
حسب: Qinglian Zhai, وآخرون
منشور في: (2022)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
حسب: Ingrid F. Metzger, وآخرون
منشور في: (2019)

Prediction of the drug-drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
حسب: Loeckie De Zwart, وآخرون
منشور في: (2021)

Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
حسب: Florian Klomp, وآخرون
منشور في: (2020)

Therapeutic Drug Monitoring of Quinidine in Pediatric Patients with <i>KCNT1</i> Genetic Variants
حسب: Alessandro Ferretti, وآخرون
منشور في: (2022)

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp
حسب: Tingting Zhao, وآخرون
منشور في: (2022)

No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P‐glycoprotein (P‐gp) drug transporter
حسب: Jordi Aubets, وآخرون
منشور في: (2019)

Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model
حسب: Udomsak Udomnilobol, وآخرون
منشور في: (2024)

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
حسب: Alison E. Fohner, وآخرون
منشور في: (2020)

CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System-Results From the ADRED Study
حسب: Katja S. Just, وآخرون
منشور في: (2021)

Quinidine in Treatment of Migrating Partial Seizures of Infancy
حسب: J Gordon Millichap, وآخرون
منشور في: (2014)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
حسب: Saaket Agrawal, وآخرون
منشور في: (2020)

Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru
حسب: Angel T. Alvarado, وآخرون
منشور في: (2023)